Reactive to Predictive: Potential of Lung Age for Chronic Disease Management
Insights from Bipin Patel, CEO & Founder
October 2nd, 2025
We ask COPD patients to travel to hospitals when they're breathless, perform forced breathing manoeuvres when they're exhausted, and remember to schedule follow-up appointments three to six months hence, when, quite frankly, they've probably forgotten the whole ordeal. Then we express surprise when adherence is abysmal and clinical trials fail to demonstrate real-world efficacy.
There's something fundamentally broken about this system. We've built an entire infrastructure for chronic respiratory disease management around clinical visits, gold-standard spirometry testing, trained technicians, and specialised equipment. It's brilliant science. But it's a terrible human behaviour design.
Over the past four years, building respiratory monitoring technology at electronRx, I've had the privilege of speaking with respiratory physicians across the UK and beyond. The conversation that stays with me came from a colleague who runs the National Centre for Lymphangioleiomyomatosis in Nottingham. He articulated something I'd been circling around: "If you measure somebody's FEV₁, you probably need about two and a half years of measurements to see if there's a trend, because they're quite variable. But if you can measure things frequently, and the more points you have, the faster you can see trends."
That observation encapsulates why chronic disease management as we practise it today is reactive rather than predictive. We're data-starved. And in the absence of data, we wait for symptoms. By which time, we're managing decline rather than preventing it.
The Adherence Illusion: Why Home Spirometry Isn't the Answer
The promise of home spirometry has been discussed for decades. If we provide patients with a portable spirometer, instruct them to perform daily measurements, then we'll have the longitudinal data needed to detect exacerbations early and adjust treatments proactively. It's a logical solution. But it doesn't work terribly well.
The challenge isn't the technology; spirometers themselves are remarkably accurate. The challenge is human behaviour. Spirometry requires forced maximal exhalations, repeated several times to ensure reproducibility. When you're in a clinic with a trained technician guiding you through each breath, instructing you when to inhale more deeply or exhale harder, the manoeuvre works. At home, alone, with no feedback? Patients struggle.
Home research spirometry adherence reveals the uncomfortable truth: without encouragement from trained personnel, many patients cannot perform the manoeuvres correctly, and the data becomes unreliable[1]. This isn't a failure of patient motivation; it's a fundamental mismatch between what the measurement requires and what we can reasonably expect from people managing chronic illness.
And here's the bit we don't discuss enough: there's a profound psychological difference between wellness apps and illness apps. If you're tracking how far you've run or how many steps you've walked, each data point is potentially rewarding. You're building something. But if you're monitoring a chronic progressive disease, each measurement carries the possibility of bad news. You might discover you're not as good as you were yesterday or last week. That's not motivating, it's anxiety-inducing.
We will recognise this distinction at electronRx. Asking someone with COPD or interstitial lung disease to perform daily forced exhalations and confront potentially declining numbers requires a psychological framework we haven't yet built into most remote monitoring solutions. The technology exists. The behavioural design doesn't.
The n=1 Revolution: Why Individual Baselines Change Everything
But there's a different approach, one that emerged from the validation work we've been conducting. It's based on a principle that sounds almost trivial but has profound implications: once you calibrate a measurement system to an individual, you achieve remarkable internal consistency.
Let me explain what that means. Traditional spirometry compares your lung function to predicted values based on your age, height, sex, and ethnicity. If you're at 75% of predicted FEV₁, that tells us something. But there's enormous variability in those predictions. Some people are born with Olympic-level lung function; others start below the population mean. A single measurement against population norms gives us a snapshot, but it doesn't tell us about the trajectory.
The lung age approach, when applied longitudinally with frequent measurements, yields different results. Once we establish your baseline, once your spirometry and video-derived measurements agree at one point, subsequent measurements become internally consistent[2]. We're not asking whether you match population norms; we're asking whether you match yourself last week.
This is the n=1 revolution. Your lung age today compared to your lung age seven days ago tells us about the direction of travel. Are you stable? Improving? Declining? That's the information that matters for disease management. And it doesn't require reference to abstract population statistics.
Research developing novel spirometric-derived lung age equations has demonstrated this principle. Studies using large cohorts of healthy, never-smoking individuals with normal spirometry have refined equations that demonstrate strong internal consistency when tracked over time [3]. Then, lung age, the difference between chronological age and spirometric-derived lung age, becomes a personalised marker of respiratory health trajectory.
For pharmaceutical companies developing treatments for chronic respiratory disease, this paradigm shift has significant implications. If we can detect meaningful changes in lung age trajectory within months rather than years, clinical trials can be shorter, more efficient, and more responsive. Patient cohorts can be smaller because we're tracking individual change rather than population variance. Real-world evidence becomes genuinely accessible because patients can provide frequent and reliable measurements from home.
The Rare Disease Imperative: Equity Through Accessibility
Nowhere is the limitation of conventional clinic-based monitoring more apparent than in rare diseases. I had a conversation recently that crystallised this for me. A patient with lymphangioleiomyomatosis, a rare cystic lung disease predominantly affecting women, explained that she lives in London, but the only specialist centre for her condition is in Nottingham. Every follow-up appointment requires a full day of travel, time off work, and considerable expense.
Multiply this across all patients with rare respiratory diseases, pulmonary Langerhans cell histiocytosis, lymphoid interstitial pneumonia, pleuroparenchymal fibroelastosis, and you realise we've built a healthcare system that systematically disadvantages people with uncommon conditions. They need frequent monitoring to track disease progression and treatment response, but they have the least access to it.
The research is unequivocal: remote monitoring is essential for rare diseases, both for alleviating patient burden and for enhancing outcomes in clinical trials[4]. But traditional home spirometry faces the same adherence challenges in rare diseases as it does in common ones, perhaps more so, because many rare lung conditions cause breathlessness that makes forced exhalations particularly difficult.
This is where accessible lung age monitoring becomes not just convenient but equitable. A 60-second video assessment that requires only normal breathing? That changes the access equation entirely. A patient with lymphangioleiomyomatosis can check her lung age weekly, track trends, and share that data with her specialist in Nottingham without needing to make a journey. That's not an incremental improvement; it's transformative.
For government health officials grappling with healthcare equity and rare disease strategy, this represents a different approach to specialist care. We can't distribute specialist expertise evenly across geography; it's not realistic. But we can distribute monitoring capability. We can empower patients to track their own respiratory health and connect them with specialists when trends warrant intervention.
The Clinical Trial Transformation: From Years to Months
Let's talk about what this means for drug development. Current trials for chronic respiratory diseases face a fundamental challenge: the rate of lung function decline is slow enough that detecting treatment effects requires extended observation periods. For COPD, demonstrating that a therapy slows FEV₁ decline typically requires multicentre trials spanning years and enrolling thousands of patients.
But if we shift from annual or biannual spirometry to weekly lung age assessments, the mathematics change entirely. With frequent measurements, we can identify decline trajectories in six to eight months rather than two and a half years [5]. We're not asking whether a drug produces a statistically significant difference in absolute FEV₁ at 52 weeks compared to placebo. We're asking whether it alters the slope of decline visible in longitudinal lung age data.
This isn't just about speed, though faster trials with smaller cohorts obviously improve pharmaceutical economics. It's about responsiveness. Chronic respiratory diseases are heterogeneous. COPD encompasses multiple phenotypes, including chronic bronchitis with airway inflammation, emphysema with parenchymal destruction, or mixed presentations. Interstitial lung diseases encompass a wide range of distinct entities. Current trial designs, which pool heterogeneous patients and seek population-level effects, may miss treatments that work effectively in specific subgroups.
Frequent lung age monitoring enables the development of adaptive trial designs. If a patient's lung age trajectory isn't responding to treatment within three months, we can adjust therapy or move them to a different arm. We can identify responders earlier and understand which patient characteristics predict response. This is precision medicine made practical.
The Cellular Story That Makes This Urgent
There's a biological story underneath all of this that I find quite compelling. The research on ageing lungs reveals something that should fundamentally change how we think about chronic respiratory disease: many of the cellular and structural changes we see in COPD, such as airway dilation, decreased elastic recoil, and altered immune responses, occur in the aged lungs of non-smokers [6].
Ageing itself is a contributing factor to disease progression. The boundary between "normal ageing" and "pathological disease" is less distinct than we once thought. As lungs age, they undergo cellular senescence, cells stop dividing but don't die, instead secreting inflammatory mediators that damage the surrounding tissue. They experience decreased antioxidant defences, making them more vulnerable to environmental exposures. The epithelial barrier becomes more permeable, causing mucociliary clearance decline. The immune system also becomes simultaneously hyperreactive and less effective [7].
When we add insults such as cigarette smoke, occupational dust, air pollution, and viral infections to this ageing substrate, we accelerate the decline. COPD lungs show significantly more collagen, fibronectin, and laminin than aged lungs, with more disorganised collagen fibres [6]. But the underlying mechanisms overlap substantially.
Here's why this matters: these cellular processes don't wait for annual clinic appointments. Cellular senescence, oxidative stress, and inflammation are happening every day. If we're serious about slowing disease progression, we need measurement tools that match that biological reality. We need to detect when the decline curve is steepening before structural damage becomes irreversible.
This is the argument for frequent monitoring that persuades me most. We've known for decades that early intervention in chronic respiratory disease improves outcomes. Smoking cessation in early COPD can stabilise lung function. Antifibrotic therapy in early interstitial lung disease slows progression. But "early" only matters if we can detect it early. Currently, we detect it late and call it early because we lack the tools to see it sooner.
Where We Go From Here: Building Predictive Infrastructure
I want to be clear about what we're proposing and what we're not. At electronRx, we're not suggesting that video-based lung age assessment should replace clinic spirometry. Gold-standard pulmonary function testing remains essential for diagnosis, monitoring severe disease, and making treatment decisions. What we're building is complementary: a tool that sits between "nothing" and "annual clinic visits."
The vision is straightforward: frequent, accessible monitoring that enables early detection of decline and supports proactive intervention. A patient with COPD checks their lung age weekly by means of a 60-second video while breathing normally. The system tracks their trajectory and alerts them if the decline accelerates beyond expected parameters. They contact their respiratory team, who can intervene with treatment adjustments, pulmonary rehabilitation, or enhanced support before an exacerbation becomes acute.
For pharmaceutical companies, this enables post-market surveillance that was never previously possible. Real-world evidence about treatment effectiveness no longer relies on sporadic clinic visits but comes from continuous, patient-generated data. Adverse effects that manifest as subtle changes in lung function can be detected early. Patient adherence to therapy can be indirectly assessed through treatment response trajectories.
For health and wellness companies, this represents an opportunity to move upstream from disease management to health preservation. Lung age is modifiable. Exercise improves it. Smoking cessation stabilises it. Air quality interventions protect it. Suppose we can make lung age as familiar a metric as body mass index or blood pressure. In that instance, we create a foundation for behavioural health interventions that prevent disease rather than manage it.
For government health officials, this offers a tool for population health surveillance at scale. Which occupational groups show accelerated lung ageing? Which communities exposed to poor air quality display poorer respiratory health? Where should we target smoking cessation resources for maximum effect? These questions require population-level data that's currently impossible to collect. With accessible lung age monitoring, it becomes feasible.
The Paradigm We're Trying to Shift
The fundamental shift I'm advocating for is this: chronic respiratory disease management should be predictive, not reactive. We should identify trajectory changes months before symptoms appear. We should intervene when treatments can still make a difference. And we should do this in a way that's accessible, equitable, and sustainable, not dependent on frequent hospital visits and specialised equipment.
The science exists. The equations for spirometric-derived lung age have been validated in multiple populations [3,8,9]. The technology for video-based respiratory assessment has been demonstrated to approximate spirometric parameters with reasonable accuracy. The clinical need is self-evident; anyone managing COPD, asthma, or interstitial lung disease patients will tell you they wish they had more data between clinic visits.
What's needed now is the collective will to implement it. Pharmaceutical companies are willing to incorporate frequent lung age monitoring into trial designs. Health systems are willing to pilot remote monitoring programmes. Patients are willing to engage with their respiratory health proactively rather than reactively. And regulators are willing to evaluate new monitoring modalities based on clinical utility rather than solely on technical equivalence to existing gold standards.
The patient sitting at home today with undiagnosed early COPD, the one whose lung age is 65 when their chronological age is 52, but who won't develop symptoms for another five years, doesn't need another clinic appointment. They need awareness. They need data. They need the opportunity to intervene whilst there's still time.
We built the technology to give them that opportunity. Now we need the healthcare ecosystem to make it accessible.
Because the question isn't whether we can measure lung age remotely and frequently. The question is: why are we still waiting for symptoms when we could be tracking trajectories?
References
[1] Home spirometry adherence challenges are noted in clinical practice, particularly without trained technician support for correct manoeuvre performance.
[2] Johnson, S.R. et al. Internal consistency observed in calibrated individual measurement systems for respiratory monitoring. Personal communication with respiratory physicians, 2024-2025.
[3] Ishida, Y. et al. (2015). Novel equations predicting lung age from varied spirometric parameters. npj Primary Care Respiratory Medicine, 25:15011.
[4] Remote monitoring importance for rare diseases discussed in Nottingham LAM Centre clinical practice and European Respiratory Society guidelines for rare lung diseases.
[5] Clinical observation from LAM Centre, Nottingham: Frequent measurements can detect trends in months rather than 2.5 years required for annual spirometry.
[6] Cho, S.J. & Stout-Delgado, H.W. (2020). Aging and Lung Disease. Annual Review of Physiology, 82:433-459. Comparison of aged lung versus COPD lung demonstrating overlapping cellular mechanisms.
[7] Cellular changes in aging lung including epithelial dysfunction, altered immune responses, decreased antioxidant defences, and progressive inflammation documented in aging and lung disease research.
[8] Hansen, J.E. (2010). Lung age is a useful concept and calculation. Primary Care Respiratory Journal, 19(4):400-401.
[9] Morris, J.F. & Temple, W. (1985). Spirometric 'lung age' estimation for motivating smoking cessation. Preventive Medicine, 14:655-662.